AVALO THERAPEUTICS, INC. Proceeds from Issuance of Secured Debt
AVALO THERAPEUTICS, INC. (AVTX) reported Proceeds from Issuance of Secured Debt of $0 for the 12-month period ending 2016-12-31, per its 10-K filed 2017-03-14.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfSecuredDebt · last filed 2017-03-14
- AVALO THERAPEUTICS, INC. proceeds from issuance of secured debt for the quarter ending 2014-12-31 was $0.00.
- AVALO THERAPEUTICS, INC. proceeds from issuance of secured debt for fiscal 2016 was $0.00.
- AVALO THERAPEUTICS, INC. proceeds from issuance of secured debt for fiscal 2015 was $0.00, a 100.00% decline from fiscal 2014.
- AVALO THERAPEUTICS, INC. proceeds from issuance of secured debt for fiscal 2014 was $7.39M.
| Period end | Proceeds from Issuance of Secured Debt 3 month | Proceeds from Issuance of Secured Debt 9 month | Proceeds from Issuance of Secured Debt 12 month |
|---|---|---|---|
| 2016-12-31 | $0.00 10-K · filed 2017-03-14 | ||
| 2015-12-31 | $0.00 10-K · filed 2017-03-14 | ||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-14 | $7.39M 10-K · filed 2017-03-14 | |
| 2014-09-30 | $7.39M 10-Q · filed 2015-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |